Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Treatment of shock using adrenomedullin binding protein-1

a technology of adrenomedullin and binding protein, which is applied in the direction of drug composition, peptide/protein ingredients, endocrine system disorders, etc., can solve the problems of difficult identification of one or two, and achieve the effect of reducing preventing or treating the physiologic effect of shock in a mammal

Inactive Publication Date: 2005-08-18
WANG PING
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The patent is about a new discovery that a protein called adrenomedullin binding protein-1 (AMBP-1) is in short supply in shock. When AMBP-1 is added to mammals, it reduces the harmful effects of shock. The patent describes methods for using AMBP-1 to treat or prevent shock in mammals. The technical effect of the patent is that it provides a new way to protect against or treat shock by adding a specific protein to mammals."

Problems solved by technology

Although these three stages are believed to be present in all cases of shock, the duration of each stage can vary widely, depending on the severity and type of shock, such that it may be difficult to identify one or two of the stages.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of shock using adrenomedullin binding protein-1

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0041] It was observed in studies in rats that adrenomedullin (100 nM)+AMBP-1 (50 nM) reduced endotoxin (100 ng / ml)-stimulated release of TNF-α (Wu et al., 2003). This suggests that adrenomedullin is an anti-inflammatory factor. In the current study, the significant rise in serum levels of TNF-α, IL-1β and IL-6 seen at 20 h after the onset of sepsis in the vehicle-treated animals was significantly blunted in the animals treated with adrenomedullin+AMBP-1. In line with the beneficial effect of adrenomedullin+AMBP-1 on the cardiovascular response, it is probable that down-regulation of proinflammatory cytokines by adrenomedullin+AMBP-1 is one of the mechanisms responsible for the beneficial effects of these agents observed during sepsis. The plasma level of adrenomedullin was found to be reduced at 20 h after CLP in animals treated with adrenomedullin+AMBP-1 as compared with vehicle-treated animals. This apparently paradoxical result is explained by the fact that the available adrenom...

example 2

Modulation of Vascular Responsiveness to Adrenomedullin after Hemorrhagic Shock: Beneficial Effects of Adrenomedullin and Adrenomedullin Binding Protein-1 (AMBP-1)

[0059] Introduction. Our preliminary results indicate that vascular responsiveness to adrenomedullin is depressed after hemorrhage and resuscitation. Downregulation of AMBP-1 expression appears to be responsible for this hyporesponsiveness. In addition, AMBP-1 attenuates vascular adrenomedullin hyporesponsiveness induced by hemorrhage under in vivo conditions.

[0060] Hypothesis. Administration of adrenomedullin and AMBP-1 improves cardiovascular function after hemorrhagic shock under in vivo conditions.

[0061] Methods. Male rats (275-325 g) were bled to and maintained at a mean blood pressure of 40 mm Hg for 90 min. There were then resuscitated with four times the volume of shed blood in the form of Ringer's lactate over 60 min. At 15 min after the beginning of resuscitation in hemorrhaged animals, adrenomedullin (12 μg / k...

example 3

Mechanisms Responsible for the Reduced Microvascular Responsiveness to Adrenomedullin after Hemorrhage: the Central Role of Adrenomedullin Binding Protein-1 (AMBP-1)

[0064] Irreversible hypovolemia remains a major clinical problem. Preliminary studies indicate that administration of adrenomedullin+AMBP-1 after hemorrhage improves cardiovascular function despite the increased levels of adrenomedullin. The aim of this study was to determine whether vascular responsiveness to adrenomedullin is reduced after hemorrhage and, if so, to elucidate the mechanism responsible for adrenomedullin hyporesponsiveness.

[0065] Methods. Male rats (275-325 g) were bled to and maintained at a BP of 40 mm Hg for 90 min. They were then resuscitated with 4 times the volume of shed blood in the form of Ringer's lactate over 60 min. At 1.5 h post-resuscitation (Rs), the vascular response to adrenomedullin (10−7 M) and AMBP-1 (2×10−8 M) was determined by using an isolated gut preparation. Blood and tissue sa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
volumeaaaaaaaaaa
concentrationaaaaaaaaaa
body weightaaaaaaaaaa
Login to View More

Abstract

Methods of treating a mammal in shock or at risk for shock are provided. The methods involve administration of an adrenomedullin binding protein-1 to the mammal. Also provided are methods of preventing or treating a physiologic effect of shock in a mammal. These methods also involve administration of an adrenomedullin binding protein-1 to the mammal.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This is a continuation of application Ser. No. 10 / 729,193, filed Dec. 5, 2003, which is a continuation-in-part of application Ser. No. 10 / 439,762, filed May 16, 2003, incorporated by reference in its entirety.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT [0002] The U.S. Government has a paid-up license in this invention and the right in limited circumstances to require the patent owner to license others on reasonable terms as provided for by the terms of Grant Nos. RO1 GM57468, GM53008, and KO2 A101461, awarded by the National Institutes of Health.BACKGROUND OF THE INVENTION [0003] (1) Field of the Invention [0004] This invention generally relates to treatment of shock. More specifically, the invention is directed to the administration of adrenomedullin binding protein-1 to mammals in shock or at risk for shock. [0005] (2) Description of the Related Art REFERENCES CITED [0006] Elsasser T H, Kahl S, Martinez A, Montueng...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/22
CPCA61K38/22A61K38/1709A61K2300/00
Inventor WANG, PING
Owner WANG PING
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com